|
1
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wesolowski R, Lee C and Kim R: Is there a
role for second-line chemotherapy in advanced gastric cancer?
Lancet Oncol. 10:903–912. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kim HJ and Oh SC: Novel systemic therapies
for advanced gastric cancer. J Gastric Cancer. 18:1–19. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Satolli MA, Buffoni L, Spadi R and Roato
I: Gastric cancer: The times they are a-changin’. World J
Gastrointest Oncol. 7:303–316. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gattinoni L, Powell DJ Jr, Rosenberg SA
and Restifo NP: Adoptive immunotherapy for cancer: Building on
success. Nat Rev Immunol. 6:383–393. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yee C: The use of endogenous T cells for
adoptive transfer. Immunol Rev. 257:250–263. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ernst B and Anderson KS: Immunotherapy for
the treatment of breast cancer. Curr Oncol Rep. 17:52015.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sheu BC, Chiou SH, Chang WC, Chow SN, Lin
HH, Chen RJ, Huang SC, Ho HN and Hsu SM: Integration of high-risk
human papillomavirus DNA correlates with HLA genotype aberration
and reduced HLA class I molecule expression in human cervical
carcinoma. Clin Immunol. 115:295–301. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Watanabe Y, Saito M, Saito K, Matsumoto Y,
Kanke Y, Onozawa H, Hayase S, Sakamoto W, Ishigame T, Momma T, et
al: Upregulated HOXA9 expression is associated with lymph node
metastasis in colorectal cancer. Oncol Lett. 15:2756–2762.
2018.PubMed/NCBI
|
|
10
|
Sakakibara M, Kanto T, Hayakawa M, Kuroda
S, Miyatake H, Itose I, Miyazaki M, Kakita N, Higashitani K,
Matsubara T, et al: Comprehensive immunological analyses of
colorectal cancer patients in the phase I/II study of quickly
matured dendritic cell vaccine pulsed with carcinoembryonic antigen
peptide. Cancer Immunol Immunother. 60:1565–1575. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Masuzawa T, Fujiwara Y, Okada K, Nakamura
A, Takiguchi S, Nakajima K, Miyata H, Yamasaki M, Kurokawa Y, Osawa
R, et al: Phase I/II study of S-1 plus cisplatin combined with
peptide vaccines for human vascular endothelial growth factor
receptor 1 and 2 in patients with advanced gastric cancer. Int J
Oncol. 41:1297–1304. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Mackensen A, Meidenbauer N, Vogl S, Laumer
M, Berger J and Andreesen R: Phase I study of adoptive T-cell
therapy using antigen-specific CD8+ T cells for the treatment of
patients with metastatic melanoma. J Clin Oncol. 24:5060–5069.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kavanagh B, Ko A, Venook A, Margolin K,
Zeh H, Lotze M, Schillinger B, Liu W, Lu Y, Mitsky P, et al:
Vaccination of metastatic colorectal cancer patients with matured
dendritic cells loaded with multiple major histocompatibility
complex class I peptid. J Immunother. 30:762–772. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Strober W: Trypan blue exclusion test of
cell viability. Curr Protoc Immunol. 111:A3.B.1–3. 2015. View Article : Google Scholar
|
|
15
|
Wang M, Yin B, Wang HY and Wang RF:
Current advances in T-cell-based cancer immunotherapy.
Immunotherapy. 6:1265–1278. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Carluccio S, Delbue S, Signorini L, Setola
E, Bagliani A, Della Valle A, Galli A, Ferrante P and Bregni M:
Generation of tumor-specific cytotoxic T-lymphocytes from the
peripheral blood of colorectal cancer patients for adoptive T-cell
transfer. J Cell Physiol. 230:1457–1465. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Khammari A, Labarrière N, Vignard V,
Nguyen JM, Pandolfino MC, Knol AC, Quéreux G, Saiagh S, Brocard A,
Jotereau F and Dreno B: Treatment of metastatic melanoma with
autologous Melan-A/MART-1-specific cytotoxic T lymphocyte clones. J
Invest Dermatol. 129:2835–2842. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhang GQ, Zhao H, Wu JY, Li JY, Yan X,
Wang G, Wu LL, Zhang XG, Shao Y, Wang Y and Jiao SC: Prolonged
overall survival in gastric cancer patients after adoptive
immunotherapy. World J Gastroenterol. 21:2777–2785. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Karimi S, Chattopadhyay S and Chakraborty
NG: Manipulation of regulatory T cells and antigen-specific
cytotoxic T lymphocyte-based tumour immunotherapy. Immunology.
144:186–196. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lake RA and Robinson BW: Immunotherapy and
chemotherapy-a practical partnership. Nat Rev Cancer. 5:397–405.
2005. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ghiringhelli F, Menard C, Puig PE, Ladoire
S, Roux S, Martin F, Solary E, Le Cesne A, Zitvogel L and Chauffert
B: Metronomic cyclophosphamide regimen selectively depletes
CD4+CD25+ regulatory T cells and restores T and NK effector
functions in end stage cancer patients. Cancer Immunol Immunother.
56:641–648. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Scurr M, Pembroke T, Bloom A, Roberts D,
Thomson A, Smart K, Bridgeman H, Adams R, Brewster A, Jones R, et
al: Low-dose cyclophosphamide induces antitumor T-cell responses,
which associate with survival in metastatic colorectal cancer. Clin
Cancer Res. 23:6771–6780. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Peng S, Lyford-Pike S, Akpeng B, Wu A,
Hung CF, Hannaman D, Saunders JR, Wu TC and Pai SI: Low-dose
cyclophosphamide administered as daily or single dose enhances the
antitumor effects of a therapeutic HPV vaccine. Cancer Immunol
Immunother. 62:171–182. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Suzuki E, Kapoor V, Jassar AS, Kaiser LR
and Albelda SM: Gemcitabine selectively eliminates splenic
Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and
enhances antitumor immune activity. Clin Cancer Res. 11:6713–6721.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sevko A, Michels T, Vrohlings M, Umansky
L, Beckhove P, Kato M, Shurin GV, Shurin MR and Umansky V:
Antitumor effect of paclitaxel is mediated by inhibition of
myeloid-derived suppressor cells and chronic inflammation in the
spontaneous melanoma model. J Immunol. 190:2464–2471. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Vincent J, Mignot G, Chalmin F, Ladoire S,
Bruchard M, Chevriaux A, Martin F, Apetoh L, Rébé C and
Ghiringhelli F: 5-Fluorouracil selectively kills tumor-associated
myeloid-derived suppressor cells resulting in enhanced T
cell-dependent antitumor immunity. Cancer Res. 70:3052–3061. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kimura H, Matsui Y, Ishikawa A, Nakajima
T, Yoshino M and Sakairi Y: Randomized controlled phase III trial
of adjuvant chemo-immunotherapy with activated killer T cells and
dendritic cells in patients with resected primary lung cancer.
Cancer Immunol Immunother. 64:51–59. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lutzky VP, Crooks P, Morrison L, Stevens
N, Davis JE, Corban M, Hall D, Panizza B, Coman WB, Coman S and
Moss DJ: Cytotoxic T cell adoptive immunotherapy as a treatment for
nasopharyngeal carcinoma. Clin Vaccine Immunol. 21:256–259. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Fournier C, Martin F, Zitvogel L, Kroemer
G, Galluzzi L and Apetoh L.: Trial Watch: Adoptively transferred
cells for anticancer immunotherapy. Oncoimmunology. 6:e13631392017.
View Article : Google Scholar : PubMed/NCBI
|
